Abbott Laboratories (ABT) is currently trading at $100.57. Based on 24 Wall Street analysts, the average target price is $118.67, implying a 18.0% upside. The consensus recommendation is BUY.

ABT

Abbott Laboratories

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$100.57

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$112.00$134.00
Current $100.57
Median: $119.00Mean: $120.00Current: $100.57

Recent price target updates (latest 80)

  • CitigroupJul 17, 2026

    PT action: Raises

    $108.00 → $112.00

  • Piper SandlerJul 17, 2026

    PT action: Raises

    $115.00 → $118.00

  • JP MorganJul 17, 2026

    PT action: Raises

    $110.00 → $120.00

  • Wells FargoJul 17, 2026

    PT action: Raises

    $109.00 → $112.00

  • TD CowenJul 17, 2026

    PT action: Maintains

    $115.00 → $115.00

  • Evercore ISI GroupJul 17, 2026

    PT action: Raises

    $112.00 → $120.00

  • RBC CapitalJul 17, 2026

    PT action: Maintains

    $130.00 → $130.00

  • BTIGJul 17, 2026

    PT action: Raises

    $131.00 → $134.00

  • Evercore ISI GroupJul 6, 2026

    PT action: Lowers

    $120.00 → $112.00

  • BairdJul 1, 2026

    PT action: Announces

    $0.00 → $121.00

  • Piper SandlerJun 22, 2026

    PT action: Maintains

    $115.00 → $115.00

  • BTIGApr 27, 2026

    PT action: Maintains

    $131.00 → $131.00

  • BarclaysApr 20, 2026

    PT action: Lowers

    $144.00 → $143.00

  • Piper SandlerApr 17, 2026

    PT action: Lowers

    $135.00 → $115.00

  • OppenheimerApr 17, 2026

    PT action: Lowers

    $132.00 → $115.00

  • RBC CapitalApr 17, 2026

    PT action: Lowers

    $135.00 → $130.00

  • BenchmarkApr 17, 2026

    PT action: Lowers

    $145.00 → $120.00

  • Evercore ISI GroupApr 17, 2026

    PT action: Lowers

    $134.00 → $120.00

  • B of A SecuritiesApr 17, 2026

    PT action: Lowers

    $150.00 → $120.00

  • StifelApr 17, 2026

    PT action: Lowers

    $145.00 → $120.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$118.67

Based on 24 analysts

Analyst Recommendations

Buy (20)Hold (7)Sell (0)

Upside

+17.99%

Market Cap

$0.00B

Financial & Investment Metrics

Next Earnings Date
Oct 14, 2026D-84
P/E Ratio (TTM)32.55
Forward P/E16.58
P/B Ratio3.36
Dividend Yield2.53%
Return on Equity (ROE)N/A
Operating Margin14.15%
Debt to Equity64.77
Beta (Volatility)0.61
52 Week Range$81.97 - $137.49
LowCurrent: $100.57High

Latest News

Daily editorial mentioning ABT

Price target moves

BMO Capital Lifts GOOGL and BLK Targets Amidst Broad NFLX Revisions

As of July 20, 2026, the analyst community has been busy recalibrating expectations across key S&P 500 constituents. Most notably, BMO Capital initiated a series of adjustments on July 17, pushing their target for Alphabet (GOOGL) to $455 from $435, while simultaneously raising BlackRock (BLK) to $1300 from $1250.

Revisions this week

The activity was concentrated in the financial and healthcare sectors. Morgan Stanley (MS) saw upward adjustments from both BMO Capital (to $250) and Freedom Broker (to $245), highlighting a firming sentiment toward the banking giant. Healthcare also saw significant movement; UnitedHealth Group (UNH) captured upgrades from Morgan Stanley to $529 and Keybanc to $500.

Conversely, the downward revisions were marked by a heavy concentration in Communication Services. Netflix (NFLX) faced a barrage of target cuts from five different firms, including Goldman Sachs, JP Morgan, and Morgan Stanley, with price targets coalescing around the $83–$94 range.

Ticker Firm Dir Prior→Current
GOOGL BMO Capital Up 435→455
NFLX JP Morgan Down 118→85
ISRG Piper Sandler Down 580→470
MS BMO Capital Up 240→250

What to notice

The divergence in Healthcare targets is particularly striking. While Piper Sandler and Raymond James took a sharper stance on Intuitive Surgical (ISRG), slashing targets to $470 and $483 respectively, other corners of the sector like Elevance Health (ELV) saw Leerink Partners boost their target to $395. This suggests that while broader sector sentiment remains generally positive, specific valuation models for surgical robotics are undergoing a more aggressive reset. You can track these shifting consensus trends on our dedicated moves page.

Sector divergence in tech and energy

The IT and energy sectors saw individual, albeit significant, downward revisions that bucked the broader positive momentum seen in financials. Citigroup’s decision to drop IBM from $375 to $255 represents a substantial recalibration, signaling a move to align with more conservative valuation multiples. Similarly, the energy space saw Occidental Petroleum (OXY) pared back to $60 by Citigroup, reflecting a cooling outlook on price appreciation for the firm relative to its historical consensus.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 4Insider Sells: 6

Whale Trades (C-Level Large Buys)

Major insider buying detected recently.

STRATTON JOHN G. (Director) - 2,000 shares

Recent Insider Transactions

DateNamePositionTransactionShares
5/7/2026STRATTON JOHN G.DirectorPurchase at price 86.82 per share.2,000
4/27/2026STARKS DANIEL JDirectorPurchase at price 92.65 per share.10,000
4/23/2026BOUDREAU PHILIP PChief Financial OfficerPurchase at price 91.50 per share.2,200
3/2/2026SALVADORI DANIEL GESUA SIVEOfficerSale at price 115.58 per share.885
3/2/2026MCCOY JOHN A. JROfficerSale at price 115.58 per share.585
3/2/2026SHROFF ERICOfficerSale at price 115.58 per share.709
3/2/2026CUSHMAN ELIZABETH CGeneral CounselSale at price 115.58 per share.263
3/2/2026MORRONE LOUIS HOfficerSale at price 115.58 per share.1,144
3/2/2026MORELAND MARY KOfficerSale at price 115.58 per share.613
2/4/2026STARKS DANIEL JDirectorPurchase at price 108.33 - 109.14 per share.10,000

Frequently Asked Questions

Q. What is the current target price and upside for ABT?

A. The current target price for Abbott Laboratories is $118.67, which implies a 18.0% upside from the current price of $100.57. This is based on the consensus of 24 Wall Street analysts.

Q. What is the current analyst recommendation for ABT?

A. Currently, there are 4 Strong Buy, 16 Buy, 7 Hold, 0 Sell, and 0 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying ABT stock recently?

A. Over the past 6 months, there have been 4 insider buys and 6 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer